Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
MIT Technology Review1h
Drugs like Ozempic now make up 5% of prescriptions in the US
One out of 20 prescriptions written in the U.S. is for a GLP-1 drug. US doctors write billions of prescriptions each year.
FDA says knockoff versions of weight loss drug must come off the market
Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
WebMD14h
FDA Approves New Drug for Advanced Lung Cancer
The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).
Cochrane23h
Are non-steroidal anti-inflammatory drugs (NSAIDs) effective for treating symptomatic uncomplicated urinary tract infections in women?
The use of NSAIDs for symptomatic management of uncomplicated UTIs probably results in less short-term resolution of symptoms and greater use of rescue antibiotics by day 30 compared to primary ...
Medscape1d
FDA OKs First Mesenchymal Stromal Cell Therapy for GVHD
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...
Could a pill replace gene therapy for sickle cell disease? Research uncovers potential path to small-molecule drug
The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston ...
Harrow: The Triesence Relaunch
Harrow's relaunch of Triesence, a preservative-free corticosteroid, is revolutionizing ophthalmology with safer and more ...